ArticleArthritis research & therapy2018
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 59 citations in OpenAlex.
- AdaBoost-based differential diagnosis of gouty arthritis and rheumatoid arthritis: model construction, temporal validation, and SHAP visualization.Frontiers in medicine · 2026Article
- Multiple comorbidities and economic burden of hospitalized gout patients in Guangdong Province.Clinical rheumatology · 2025Article
- Indolelactic acid as a potential metabolic biomarker for diagnosing gout.Experimental and therapeutic medicine · 2024Article
- Structure-Activity Relationships and Changes in the Inhibition of Xanthine Oxidase by Polyphenols: A Review.Foods (Basel, Switzerland) · 2024Review
- The Evolving Landscape of Gout in the Female: A Narrative Review.Gout, urate, and crystal deposition disease · 2023Article
- Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert.Arthritis care & research · 2023Article
- Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.British journal of clinical pharmacology · 2022Article
- Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.The Journal of veterinary medical science · 2022Article
- Healthy lifestyle counteracts the risk effect of genetic factors on incident gout: a large population-based longitudinal study.BMC medicine · 2022Article
- Sleep disorders and gout in Australian adults.BMC rheumatology · 2021Article
- Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.Nature reviews. Rheumatology · 2020Review
- Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout.International journal of molecular sciences · 2020Article
- Extra-abdominal dual-energy CT applications: a comprehensive overview.La Radiologia medica · 2020Review
- Article
- Uric Acid and Plant-Based Nutrition.Nutrients · 2019Review
- Aqueous and Methanol Extracts ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Hydromethanolic Root Extract of Gnidia Kraussiana Demonstrates Anti-Inflammatory Effect Through Anti-Oxidant Activity Enhancement in a Rodent Model of Gout.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia.
methodsData were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model.
resultsSelf-reported gout prevalence was 6.8% (95% CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82% were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36% current; 29% previous) with only 55% continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT.
conclusionsDespite gout being a common, potentially disabling joint disease, only 55% of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.